Trial intelligence / Profile preview

ACTICCA-1 adjuvant gemcitabine + cisplatin versus standard of care after curative resection of biliary tract cancer

2012-005078-70Phase 3Active

Sponsor: University Medical Center Hamburg-Eppendorf
Start: Aug 2013
Modality: Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
Countries: 1

Overview

Phase 3, randomised, open-label trial of gemcitabine, cisplatin and capecitabine in cholangiocarcinoma (CCA) and gallbladder cancer (2 arms), sponsored by University Medical Center Hamburg-Eppendorf. Primary endpoint: Disease-free survival. Started Aug 2013; status: active.

Drugs

gemcitabinecisplatincapecitabine

Conditions

cholangiocarcinoma (CCA)gallbladder cancer

Beyond the preview

Go deeper on 2012-005078-70.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2012-005078-70.